Intestinal absorption, metabolism, and excretion of (-)-epicatechin in healthy humans assessed by using an intestinal perfusion technique

American Journal of Clinical Nutrition

Volumn 98, Issue 4, 2013, Pages 924-933

  Actis Goretta, Lucas ^a   Lévèques, Antoine ^a   Rein, Maarit ^a   Teml, Alexander ^b   Schäfer, Christian ^c   Hofmann, Ute ^b   Li, Hequn ^a   Schwab, Matthias ^b,d   Eichelbaum, Michel ^b   Williamson, Gary ^e  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPICATECHIN; GLUCURONIDE; PHENAZONE; SULFOTRANSFERASE;

ADULT; ARTICLE; BILE; BILIARY EXCRETION; BIOAVAILABILITY; CONJUGATE; CONJUGATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTESTINE CELL; INTESTINE FLUID; INTESTINE PERFUSION; KIDNEY CONCENTRATING CAPACITY; MALE; METABOLISM; METABOLITE; NORMAL HUMAN; OPEN STUDY; PLASMA; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE ABSORPTION; URINARY EXCRETION; URINE; WATER ABSORPTION;

ADULT; ANTIPYRINE; BILE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CATECHIN; CATHETERIZATION; DEUTERIUM; ENTEROCYTES; FEMALE; HUMANS; INTESTINAL ABSORPTION; INTESTINES; JEJUNUM; MALE; PERFUSION; SULFATES;

EID: 84884874365     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.113.065789     Document Type: Article

References (37)

1. Hertog MG. Epidemiological evidence on potential health properties of flavonoids. Proc Nutr Soc 1996;55:385-97. (Pubitemid 126795349)
2. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, Jacobs DR Jr. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr 2007; 85:895-909. (Pubitemid 46393524)
3. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-11. (Pubitemid 23314801)
4. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005;81(1 suppl):317S-25S.
5. Borges G, Mullen W, Mullan A, Lean ME, Roberts SA, Crozier A. Bioavailability of multiple components following acute ingestion of a polyphenol- rich juice drink. Mol Nutr Food Res 2010;54(suppl 2):S268-74.
6. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005;81(1 suppl):230S-42S.
7. Heiss C, Kleinbongard P, Dejam A, Perre S, Schroeter H, Sies H, Kelm M. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol 2005;46:1276-83. (Pubitemid 41615549)
8. Tinahones FJ, Rubio MA, Garrido-Sanchez L, Ruiz C, Gordillo E, Cabrerizo L, Cardona F. Green tea reduces LDL oxidability and improves vascular function. J Am Coll Nutr 2008;27:209-13.
9. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H, Kwik-Uribe C, Schmitz HH, Kelm M. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci USA 2006;103:1024-9. (Pubitemid 43212215)
10. Tam YK. Individual variation in first-pass metabolism. Clin Pharmacokinet 1993;25:300-28. (Pubitemid 23306193)
11. Farrell TL, Poquet L, Dew TP, Barber S, Williamson G. Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study. Drug Metab Dispos 2012;40:397-406.
12. Barrington R, Williamson G, Bennett RN, Davis BD, Brodbelt JS, Kroon PA. Absorption, conjugation and efflux of the flavonoids, kaempferol and galangin, using the intestinal CACO-2/TC7 cell model. J Funct Foods 2009;1:74-87.
13. Brand W, van der Wel PA, Rein MJ, Barron D, Williamson G, van Bladeren PJ, Rietjens IM. Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. Drug Metab Dispos 2008;36:1794-802.
14. Poquet L, Clifford MN, Williamson G. Transport and metabolism of ferulic acid through the colonic epithelium. Drug Metab Dispos 2008; 36:190-7.
15. Kuhnle G, Spencer JP, Schroeter H, Shenoy B, Debnam ES, Srai SK, Rice-Evans C, Hahn U. Epicatechin and catechin are O-methylated and glucuronidated in the small intestine. Biochem Biophys Res Commun 2000;277:507-12.
16. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989;96:736-49. (Pubitemid 19057595)
17. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 2000;10:195-204. (Pubitemid 30190095)
18. Glaeser H, Drescher S, Hofmann U, Heinkele G, Somogyi AA, Eichelbaum M, Fromm MF. Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin Pharmacol Ther 2004;76:230-8. (Pubitemid 39221797)
19. von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, Dent J, Somogyi AA, Eichelbaum M. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther 2001;70:217-27. (Pubitemid 32868485)
20. Knutson T, Fridblom P, Ahlstrom H, Magnusson A, Tannergren C, Lennernäs H. Increased understanding of intestinal drug permeability determined by the LOC-I-GUT approach using multislice computed tomography. Mol Pharm 2009;6:2-10.
21. Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, Plumb GW, Bacon J, O'Leary KA, Kroon PA, Knutson L, et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos 2003;31:805-13. (Pubitemid 36617672)
22. Igel S, Drescher S, Murdter T, Hofmann U, Heinkele G, Tegude H, Glaeser H, Brenner SS, Somogyi AA, Omari T, et al. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter- mediated efflux. Clin Pharmacokinet 2007;46:777-85. (Pubitemid 47347449)
23. Eichelbaum M, Ochs HR, Roberts G, Somogyi A. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. Arzneimittelforschung 1982;32:575-8. (Pubitemid 12117358)
24. Goromaru T, Matsuyama K, Noda A, Iguchi S. The measurement of plasma concentration of aminopyrine and its metabolites in man. Chem Pharm Bull (Tokyo) 1978;26:33-7.
25. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003;73:223-31. (Pubitemid 36269673)
26. Actis-Goretta L, Leveques A, Giuffrida F, Romanov-Michailidis F, Viton F, Barron D, Duenas-Paton M, Gonzalez-Manzano S, Santos- Buelga C, Williamson G, et al. Elucidation of (-)-epicatechin metabolites after ingestion of chocolate by healthy humans. Free Radic Biol Med 2012;53:787-95.
27. Lennernäs H, Ahrenstedt O, Hallgren R, Knutson L, Ryde M, Paalzow LK. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res 1992;9:1243-51.
28. Lennernäs H. Human intestinal permeability. J Pharm Sci 1998;87:403-10. (Pubitemid 28175799)
29. Del Rio D, Stalmach A, Calani L, Crozier A. Bioavailability of coffee chlorogenic acids and green tea flavan-3-ols. Nutrients 2010;2:820-33.
30. Selma MV, Espin JC, Tomas-Barberan FA. Interaction between phenolics and gut microbiota: role in human health. J Agric Food Chem 2009;57:6485-501.
31. Monagas M, Urpi-Sarda M, Sanchez-Patan F, Llorach R, Garrido I, Gomez-Cordoves C, Andres-Lacueva C, Bartolome B. Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites. Food Funct 2010;1:233-53.
32. Tzounis X, Rodriguez-Mateos A, Vulevic J, Gibson GR, Kwik-Uribe C, Spencer JP. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am J Clin Nutr 2011;93:62-72.
33. Teubner W, Meinl W, Florian S, Kretzschmar M, Glatt H. Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem J 2007;404:207-15. (Pubitemid 46849592)
34. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9:3312-9. (Pubitemid 37082725)
35. Zhang H, Tolonen A, Rousu T, Hirvonen J, Finel M. Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells. Drug Metab Dispos 2011;39: 456-64.
36. Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon GL. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 2002;19: 1400-16. (Pubitemid 35266543)
37. Ottaviani JI, Momma TY, Kuhnle GK, Keen CL, Schroeter H. Structurally related (-)-epicatechin metabolites in humans: Assessment using de novo chemically synthesized authentic standards. Free Radic Biol Med 2012;52:1403-12.